Article Sidebar

Download
View Article
Statistic
Read Counter : 2 Download : 10

Main Article Content

Abstract

Background: Cervical cancer (CC) remains a significant oncological challenge, as its early detection and intervention can substantially improve patient outcomes, including overall and recurrence-free survival, enhance quality of life, and reduce treatment costs. Specific Background: The primary etiological factor for cervical cancer is infection with oncogenic genotypes of the human papillomavirus (HPV), which is preventable through effective screening measures. Knowledge Gap: Despite the availability of screening tests, there remains a critical need for advancements in diagnostic technologies to enhance early detection rates and precision in identifying precancerous lesions and invasive cancer. Aims: This study aims to evaluate the impact of innovative technologies on the early diagnosis of precancerous conditions and cervical cancer, focusing on improvements in diagnostic accuracy, early detection, and subsequent patient management. Results: The integration of novel diagnostic technologies, such as advanced HPV testing methods, liquid biopsy techniques, and high-resolution imaging, has demonstrated significant improvements in detecting cervical abnormalities at earlier stages compared to traditional methods. These technologies enhance diagnostic precision and enable more targeted interventions. Novelty: This research highlights recent advancements in diagnostic technologies that offer higher sensitivity and specificity, including the use of biomarkers and novel imaging modalities, which represent a shift towards more personalized and effective cervical cancer screening strategies. Implications: The findings underscore the potential for these innovative technologies to revolutionize cervical cancer screening and diagnosis, ultimately leading to improved patient outcomes, reduced healthcare costs, and more effective management of cervical cancer and its precursors.

Keywords

Diseases Of The Cervix Oncogenic Types Of HPV Minimally Invasive Methods Early Diagnosis

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite
Bakhtiyarovna, I. D. ., & Rafikovna, F. Y. (2024). INNOVATIVE TECHNOLOGIES IN EARLY DIAGNOSIS OF PRECANCER AND CANCER DISEASES OF THE CERVIX. Journal of Medical Genetics and Clinical Biology, 1(9), 5–9. https://doi.org/10.61796/jmgcb.v1i9.915
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Sukhikh GT, Prilepskaya VN, ed. Prevention of cervical cancer: A guide for doctors. 3rd ed. Moscow: MEDpress-inform; 2018. 192p.
  2. Stern P.L., G.S. Kitchener G.S., eds. Vaccine for the prevention of cervical cancer: Per. from English Sukhikh G.T., Prilepskaya V.N., ed.M.: MEDpress-inform; 2019.192c
  3. Rogovskaya S.I. Papillomavirus infection in women and pathology of the cervix: to help the practitioner. 2nd ed. Moscow: GEOTAR-Media; 2018. 192c
  4. Bleotu C., Botezatu A., Goia C.D., Socolov D., Corniţescu F., Teleman S. et al. P16ink4A-A possible marker in HPV persistence screening. room. Arch. microbiol. Immunol. 2019; 68(3): 183–9.
  5. Davey E., Barratt A., Irwig L., Chan S.F., Macaskill P., Mannes P., Saville A.M. Effect of study design and quality on unsatisfactory rates, cytology classifications, and accuracy in liquid-based versus conventional cervical cytology: a systematic review. Lancet. 2016; 376(9505): 122–32.
  6. Franco E.L., Harper D.M. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine. 2015; 23(17–18): 2388–94.
  7. Hutchcraft M. L. et al. Conization pathologic features as a predictor of intermediate and high risk features on radical hysterectomy specimens in early stage cervical cancer // Gynecologic oncology. - 2019. - T. 153. - No. 2. – P. 255-258.
  8. Muñoz N., Bosch F.X., Castellsagué X., Díaz M., de Sanjose S., Hammouda D. et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int. J. Cancer. 2020; 111(2): 278–85.
  9. Nuovo J., Melnikow J., Howell L.P. New tests for cervical cancer screening. Am. fam. P hysician. 2011; 64:L780–6.
  10. Pierry D., Weiss G., Lack B., Chen V., Fusco J. Intracellular human papillomavirus E6, E7 mRNA quantification predicts CIN 2+ in cervical biopsies better than Papanicolaou screening for women regardless of age. Arch. Pathol. Lab. Med. 2012; 136(8): 956–60.
  11. Ramirez P., Frumovitz M., Pareja R. et.al. Phase III randomized trial of laparoscopic or robotic radical hysterectomy vs. abdominal radical hysterectomy in patients with early-stage cervical cancer: LACC Trial. N Engl J Med 2018;379(20):1895–904.
  12. Snijders P., van den Brule A., Meijer C. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J. Pathol. 2019; 201(1)
  13. Kurman R.J., Carcangiu M.L., Harrington C.S. et al. (eds.) WHO Classification of Tumors of the Female Reproductive Organs. Geneva, Switzerland: WHO Press, 2018. World Health Organization Classification of Tumors. 4th edn.
  14. Webb J.C., Key C.R., Qualls C.R. et al. Population-based study of microinvasive adenocarcinoma of the uterine cervix. Obstet Gynecol 2018;97(5 Pt 1):701–6.